EICHOR
● Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Condition: Ovarian Cancer · Sponsor: Daiichi Sankyo
About this study
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
This description comes directly from the study's public registry record.
Talk to the study team
Contact for Trial Information · 908-992-6400 · CTRinfo_us@daiichisankyo.com
Always discuss trial participation with your own doctor first.
Locations (208)
| Disney Family Cancer Center | Burbank, California, United States | Recruiting |
| Scripps Clinic | La Jolla, California, United States | Recruiting |
| Palo Alto Medical Foundation | Palo Alto, California, United States | Recruiting |
| Broward Health Medical Center | Fort Lauderdale, Florida, United States | Recruiting |
| Jupiter Medical Center | Jupiter, Florida, United States | Recruiting |
| Mount Sinai Medical Center | Miami Beach, Florida, United States | Recruiting |
| AdventHealth Cancer Institute | Orlando, Florida, United States | Recruiting |
| Woman's Care FL | St. Petersburg, Florida, United States | Recruiting |
| Nancy N. & J.C Lewis Cancer & Research Pavillion- St. Josephs/ Candler Health System | Savannah, Georgia, United States | Recruiting |
| Endeavor Health Evanston Kellogg Cancer Care Center | Evanston, Illinois, United States | Recruiting |
| Indiana University | Indianapolis, Indiana, United States | Recruiting |
| Trials365 LLC | Shreveport, Louisiana, United States | Recruiting |
+ 196 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06819007